(Reuters) -Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for rare muscular dystrophy.
Shares of the company fell more than 25% to $75.86 in premarket trading.
The gene therapy, branded as Elevidys, is approved in the U.S. for patients with Duchenne muscular dystrophy aged four and older.
Acute liver injury is a known possible side effect of the therapy and mentioned in its prescribing information, the company said.
Although it is not a new safety signal, acute liver failure leading to death represents a severity of acute liver injury not previously reported for the therapy.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar and Shinjini Ganguli)
